Nitisinone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using the drug-repurposing-evaluation-report format directly (no other skill applies to this content-generation task).
Nitisinone: From Hereditary Tyrosinemia Type 1 to Renal Tubular Acidosis
One-Sentence Summary
Nitisinone (DB00348) is used to treat Hereditary Tyrosinemia Type 1 (HT-1) by blocking the tyrosine degradation pathway. The TxGNN model predicts it may also be effective for Renal Tubular Acidosis, with 0 clinical trials and 2 publications currently supporting this direction — largely reflecting a known secondary benefit of HT-1 therapy rather than a novel mechanism.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hereditary Tyrosinemia Type 1 (HT-1) — inferred from repurposing rationale; not confirmed via Taiwan license records |
| Predicted New Indication | Renal Tubular Acidosis |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L3 |
| Taiwan Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Formal DrugBank mechanism-of-action text for nitisinone is not available in this Evidence Pack. However, the literature-derived rationale provides a clear mechanistic picture: nitisinone inhibits 4-hydroxyphenylpyruvate dioxygenase (HPPD), an enzyme upstream in the tyrosine catabolism pathway. By blocking this enzyme, nitisinone prevents the accumulation of succinylacetone, the toxic downstream metabolite responsible for both the hepatic and renal tubular damage seen in HT-1.
Renal tubular acidosis — specifically Fanconi-syndrome-type proximal tubular dysfunction — is a well-documented complication of untreated or undertreated HT-1, driven directly by succinylacetone toxicity. This means the “new indication” is not mechanistically novel; it is a known secondary therapeutic effect of nitisinone within its original disease context (HT-1), rather than an independent repurposing hypothesis in an unrelated disease area.
This distinguishes renal tubular acidosis from the other TxGNN-predicted candidates in this pack (e.g., galactosemia, glycogen storage disease, C1 inhibitor deficiency), which the rationale text explicitly flags as likely artifacts of knowledge-graph node proximity (co-occurrence in “pediatric metabolic liver disease” review articles) rather than genuine mechanistic links.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25172236 | 2014 | Cohort | Molecular Genetics and Metabolism | Describes early effect of NTBC (nitisinone) on renal tubular dysfunction in patients with hereditary tyrosinemia type 1 |
| 27109516 | 2016 | Case Series | Indian Journal of Gastroenterology | Case series of 4 children with tyrosinemia treated with NTBC; reports resolution of renal tubular abnormalities alongside normalized liver function |
US Market Information
Nitisinone is currently not marketed in Taiwan (market status: 未上市), and no license records are available in the regulatory dataset. No approved Taiwan product information can be cited at this time.
Safety Considerations
Please refer to the package insert for safety information. TFDA warnings, contraindications, and drug interaction data are currently unavailable and represent a blocking data gap (DG001) for formal safety evaluation.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic link between nitisinone and renal tubular acidosis is biologically well-grounded — it reflects an established secondary effect of HT-1 treatment rather than a speculative new pathway. However, evidence is limited to one cohort and one case-series study (no RCTs or trials specifically targeting RTA as a primary endpoint), and the drug is not currently marketed in Taiwan.
To proceed, the following is needed:
- TFDA package insert data (warnings, contraindications) — currently a Blocking gap (DG001)
- Formal DrugBank MOA documentation (DG002)
- Dedicated studies or larger cohorts evaluating renal tubular acidosis as a primary treatment endpoint (current evidence is secondary/observational within HT-1 cohorts)
- Confirmation of Taiwan marketing authorization pathway, given current “not marketed” status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.